Finasteride 1mg vs 5mg for Hair Loss
This is a research-based fact check, not medical advice. The findings summarized here come from peer-reviewed studies and are presented without added opinions. Consult a certified healthcare practitioner before making any treatment decision.
Verdict
Finasteride 1mg is the FDA-approved dose for male pattern hair loss. The 5mg dose is approved only for benign prostatic hyperplasia (prostate conditions). A meta-analysis found no significant difference in efficacy between 1mg, 5mg, and topical finasteride for hair loss outcomes. There is no clinical benefit to using 5mg for hair loss, and the higher dose is not recommended for this indication.
Key takeaways
- 1mg is the FDA-approved dose for male pattern hair loss (Propecia). 5mg is approved for prostate conditions only (Proscar).
- No significant efficacy difference between 1mg and 5mg for hair loss in meta-analysis.
- Both doses inhibit Type II 5-alpha reductase, reducing DHT in scalp and blood.
- Higher doses suppress serum DHT more (5mg: ~70%, 1mg: ~65%) but this does not translate to meaningful additional hair benefit.
- Side effects may be dose-dependent, so 5mg carries more risk for no additional hair benefit.
- Finasteride is not approved for women and is contraindicated in women who are pregnant or may become pregnant.
Approved dosing
Finasteride 1mg was approved by the FDA in 1997 specifically for the treatment of male pattern hair loss under the brand name Propecia. The 5mg tablet (Proscar) was approved earlier for benign prostatic hyperplasia (BPH) at a much higher dose for a different indication. Using 5mg for hair loss is off-label. Full context on how finasteride works and what results to expect is in our finasteride efficacy guide and in the hair restoration guide.
Efficacy comparison: 1mg vs 5mg
A comprehensive meta-analysis and systematic review found that the efficacy of finasteride 1mg/day, 5mg/day, and topical finasteride (1% solution) were not significantly different for hair loss outcomes. This finding aligns with the mechanism: both doses sufficiently inhibit Type II 5-alpha reductase to produce meaningful DHT reduction in scalp tissue. The incremental difference in DHT suppression between 1mg and 5mg does not translate to additional clinical hair benefit.
DHT suppression at different doses
Finasteride at 1mg/day reduces serum DHT by approximately 65-70% and scalp tissue DHT by approximately 64%. The 5mg dose suppresses serum DHT by approximately 70%, a modest incremental difference. Since scalp DHT suppression drives the hair loss benefit, and this is sufficiently achieved at 1mg, increasing to 5mg adds systemic DHT suppression without additional scalp benefit.
Side effects and dose
The most commonly reported side effects of finasteride are sexual in nature: reduced libido, erectile dysfunction, and ejaculation disorders. These were reported in approximately 1-2% of men in the pivotal 1mg trials. Whether sexual side effects are more common at 5mg vs 1mg has not been directly studied in large trials for the hair loss population, but the general principle of dose-dependent side effects applies. Men who have already experienced sexual side effects on 1mg should not try 5mg as an alternative.
Cutting 5mg tablets
Some men purchase 5mg finasteride tablets (which are widely available for prostate treatment) and cut them into quarters to approximate the 1mg dose, as the 5mg generic tablets are substantially cheaper. This is an off-label approach with some practical caveats: tablet splitting may produce uneven doses, and the 5mg tablets are not scored for splitting. Whether the cost saving outweighs the precision loss is a practical decision for each individual in consultation with their doctor.
Topical finasteride vs oral
Topical finasteride (not FDA-approved, compounded) achieves comparable hair count improvements to oral 1mg while producing markedly lower serum DHT suppression (approximately 4-15% vs 65% for oral). This lower systemic exposure is hypothesised to reduce systemic side effects, including sexual dysfunction. The evidence base for topical finasteride is growing but less extensive than for oral.
Evidence at a glance
| Dose/form | DHT suppression (serum) | Hair loss efficacy | FDA-approved for hair loss |
|---|---|---|---|
| 1mg oral | ~65-70% | Significant vs placebo | Yes (Propecia) |
| 5mg oral | ~70% | No significant difference vs 1mg | No (approved for BPH) |
| Topical (0.25% spray) | ~4-15% | Comparable to oral 1mg in Phase III trial | No (compounded) |
What the research cannot tell you
- Whether the small additional DHT suppression at 5mg ever produces a meaningful hair benefit in any subgroup.
- The exact rate of sexual side effects at 1mg vs 5mg in a head-to-head trial specifically for hair loss use.
- The optimal dose for men who show partial response to 1mg.
- Whether intermittent dosing (e.g. 1mg every other day) maintains efficacy equivalent to daily dosing.